JP2009514874A5 - - Google Patents

Download PDF

Info

Publication number
JP2009514874A5
JP2009514874A5 JP2008539056A JP2008539056A JP2009514874A5 JP 2009514874 A5 JP2009514874 A5 JP 2009514874A5 JP 2008539056 A JP2008539056 A JP 2008539056A JP 2008539056 A JP2008539056 A JP 2008539056A JP 2009514874 A5 JP2009514874 A5 JP 2009514874A5
Authority
JP
Japan
Prior art keywords
administered
effective amount
therapeutically effective
medicament
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008539056A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009514874A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/042950 external-priority patent/WO2007056135A1/en
Publication of JP2009514874A publication Critical patent/JP2009514874A/ja
Publication of JP2009514874A5 publication Critical patent/JP2009514874A5/ja
Pending legal-status Critical Current

Links

JP2008539056A 2005-11-04 2006-11-03 Ｓａｈａ及びペメトレキセドを用いて癌を治療する方法 Pending JP2009514874A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73395105P 2005-11-04 2005-11-04
PCT/US2006/042950 WO2007056135A1 (en) 2005-11-04 2006-11-03 Method of treating cancers with saha and pemetrexed

Publications (2)

Publication Number Publication Date
JP2009514874A JP2009514874A (ja) 2009-04-09
JP2009514874A5 true JP2009514874A5 (enExample) 2009-12-17

Family

ID=38023582

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008539097A Pending JP2009514889A (ja) 2005-11-04 2006-11-03 癌を治療するためにｓａｈａ及びボルテゾミブを用いる方法
JP2008539056A Pending JP2009514874A (ja) 2005-11-04 2006-11-03 Ｓａｈａ及びペメトレキセドを用いて癌を治療する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008539097A Pending JP2009514889A (ja) 2005-11-04 2006-11-03 癌を治療するためにｓａｈａ及びボルテゾミブを用いる方法

Country Status (7)

Country Link
US (4) US20070117815A1 (enExample)
EP (2) EP1947936A4 (enExample)
JP (2) JP2009514889A (enExample)
CN (3) CN101299921A (enExample)
AU (2) AU2006311894A1 (enExample)
CA (2) CA2636596A1 (enExample)
WO (2) WO2007056232A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003213684C1 (en) * 2002-03-04 2008-10-23 Merck Hdac Research, Llc Methods of inducing terminal differentiation
US20080113874A1 (en) * 2004-01-23 2008-05-15 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
US8017321B2 (en) * 2004-01-23 2011-09-13 The Regents Of The University Of Colorado, A Body Corporate Gefitinib sensitivity-related gene expression and products and methods related thereto
ES2553264T3 (es) 2004-05-27 2015-12-07 The Regents Of The University Of Colorado Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer
ES2534304T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
AU2006223086A1 (en) * 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
TWI415603B (zh) 2005-05-20 2013-11-21 Merck Sharp & Dohme １，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅ ｈｙｄｒｏｘａｍｉｃ ａｃｉｄ）之調配物及其製配方法
JP2009514889A (ja) * 2005-11-04 2009-04-09 メルク エンド カムパニー インコーポレーテッド 癌を治療するためにｓａｈａ及びボルテゾミブを用いる方法
US20070197568A1 (en) * 2005-11-04 2007-08-23 Paul Bunn Methods of using SAHA and Erlotinib for treating cancer
CA2627923C (en) 2005-11-10 2016-01-12 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer
EP2056808A4 (en) * 2006-08-28 2009-12-23 Univ California Small molecule potentiator of hormonal therapy for breast cancer
AU2007317921A1 (en) * 2006-11-03 2008-05-15 University Of Maryland, Baltimore Methods of using SAHA and Bortezomib for treating multiple myeloma
WO2008058287A1 (en) * 2006-11-10 2008-05-15 Syndax Pharmaceuticals, Inc. COMBINATION OF ERα+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
WO2008154402A2 (en) * 2007-06-06 2008-12-18 University Of Maryland, Baltimore Hdac inhibitors and hormone targeted drugs for the treatment of cancer
US20100267779A1 (en) * 2007-07-23 2010-10-21 Syndax Pharmaceuticals, Inc. Novel Compounds and Methods of Using Them
US20100298270A1 (en) * 2007-07-23 2010-11-25 Syndax Pharmaceuticals, Inc. Novel Compounds and Methods of Using Them
US20090149511A1 (en) * 2007-10-30 2009-06-11 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC and an mTOR Inhibitor
WO2009064300A1 (en) * 2007-11-15 2009-05-22 The Johns Hopkins University Combinations of hdac inhibitors and cytokines/growth factors
WO2009067453A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
CN101918420A (zh) * 2007-12-27 2010-12-15 无限药品股份有限公司 癌症治疗方法
CN101917853B (zh) 2007-12-27 2014-03-19 无限药品股份有限公司 立体选择性还原的方法
EP2307003A2 (en) * 2008-05-16 2011-04-13 Pharma Mar S.A. Combination therapy with pm00104 and another antitumor agent
AU2010279325B2 (en) 2009-08-05 2016-10-20 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
CN102573832B (zh) * 2009-08-25 2015-07-22 阿布拉科斯生物科学有限公司 利用紫杉烷和刺猬抑制剂的纳米颗粒组合物的联合治疗
EP2502078A1 (en) * 2009-11-20 2012-09-26 Infinity Pharmaceuticals, Inc. Methods and compositions for treating hedgehog-associated cancers
US9061037B2 (en) * 2010-03-18 2015-06-23 Innopharma, Inc. Stable bortezomib formulations
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
WO2011115688A2 (en) 2010-03-19 2011-09-22 H. Lee Moffitt Cancer Center & Research Institute Integrin interaction inhibitors for the treatment of cancer
JP2013538810A (ja) * 2010-09-01 2013-10-17 ノバルティス アーゲー Ｈｄａｃ阻害剤と血小板減少症薬との組合せ
US9394313B2 (en) 2010-09-14 2016-07-19 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
WO2012041959A1 (en) * 2010-09-30 2012-04-05 University Of Zurich Treatment of b-cell lymphoma with microrna
CN108514638A (zh) * 2011-02-17 2018-09-11 杜兰教育基金委员会 多组分组合物以及它们的用途
US20140080762A1 (en) * 2011-03-21 2014-03-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Hyd1 peptides for relapsed cancer
AU2012294326A1 (en) * 2011-08-10 2013-03-21 Merrimack Pharmaceuticals, Inc. Treatment of advanced solid tumors using combination of anti-ErbB3 immunotherapy and selected chemotherapy
WO2015048477A1 (en) 2013-09-27 2015-04-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Cyclic peptide conjugates and methods of use
US9988343B2 (en) 2013-11-05 2018-06-05 Dana-Farber Cancer Institute, Inc. Inhibitors of histone deacetylase
US10369147B2 (en) 2015-06-04 2019-08-06 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
AU2016298439B2 (en) * 2015-07-30 2018-11-08 Expression Pathology, Inc. Quantifying FR-alpha and GART proteins for optimal cancer therapy
AU2018255269B2 (en) 2017-04-17 2023-03-09 The University Of Chicago Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease
KR102040034B1 (ko) * 2017-12-13 2019-11-05 주식회사 아이큐어비앤피 페메트렉시드를 포함하는 경구용 약학 조성물 및 이의 제조방법
CN108821999A (zh) * 2018-04-26 2018-11-16 南昌大学 一种氨基酸异羟肟酸类氨肽酶n抑制剂及制备方法
EP3893863A4 (en) * 2018-12-10 2022-08-31 Translational Drug Development Llc (S)-N-HYDROXY-2-(2-(4-METHOXYPHENYL)BUTANAMIDO)THIAZOLE-5-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
CN116585216A (zh) * 2022-05-16 2023-08-15 上海中翊日化有限公司 一种含有羟基频哪酮视黄酸酯(hpr)并降低光损伤及炎症的抗衰组合物

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3895347A (en) * 1973-09-10 1975-07-15 Bridgestone Tire Co Ltd System for transmitting information of reduced pneumatic pressure of tire
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US5055608A (en) * 1988-11-14 1991-10-08 Sloan-Kettering Institute For Cancer Research Novel potent inducers of thermal differentiation and method of use thereof
US5175191A (en) * 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5608108A (en) * 1988-11-14 1997-03-04 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
KR0162654B1 (ko) * 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
USRE38506E1 (en) * 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5369108A (en) * 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5700811A (en) * 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
US6043389A (en) * 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
US6262116B1 (en) * 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
PL200861B1 (pl) * 1999-09-08 2009-02-27 Sloan Kettering Inst Cancer Pochodna kwasu suberynowego, jej zastosowanie i kompozycja farmaceutyczna
WO2001062760A2 (en) * 2000-02-25 2001-08-30 Eli Lilly And Company A NOVEL CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR
AU2001287157A1 (en) * 2000-09-12 2002-03-26 Virginia Commonwealth University Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
WO2002055017A2 (en) * 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
US20020183388A1 (en) * 2001-02-01 2002-12-05 Gudas Lorraine J. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
US6501372B2 (en) * 2001-02-02 2002-12-31 Trw Inc. Tire condition sensor communication with unique sampling on vehicle-side diversity antenna array
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
CA2450129A1 (en) * 2001-06-14 2002-12-27 Donald G. Jackson Novel human histone deacetylases
US20040132643A1 (en) * 2002-01-09 2004-07-08 Fojo Antonio Tito Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms
JP2005525345A (ja) * 2002-02-15 2005-08-25 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｔｒｘ媒介性疾患を処置する方法
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
AU2003213684C1 (en) * 2002-03-04 2008-10-23 Merck Hdac Research, Llc Methods of inducing terminal differentiation
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
CN100566711C (zh) * 2002-04-15 2009-12-09 斯隆-凯特林癌症研究院 治疗癌症的化合物及其用途
JP2005530739A (ja) * 2002-04-19 2005-10-13 セルラー ジェノミクス，インコーポレーテッド イミダゾ［１，２−ａ］ピラジン−８−イルアミン、生成方法、および使用方法
AU2003253681B2 (en) * 2002-06-24 2008-05-01 Research Development Foundation Treatment of human multiple myeloma by Curcumin
AU2003291097A1 (en) * 2002-11-20 2004-06-15 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
CA2508348C (en) * 2002-12-06 2016-07-12 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
AU2004228011A1 (en) * 2003-04-01 2004-10-21 Memorial Sloan-Kettering Cancer Center Hydroxamic acid compounds and methods of use thereof
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20050020557A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
EP1638541B1 (en) * 2003-06-27 2010-05-19 Astellas Pharma Inc. Therapeutic agent for soft tissue sarcoma
PL379887A1 (pl) * 2003-08-26 2006-11-27 Merck Hdac Research, Llc Sposób leczenia raka inhibitorami HDAC
CA2535889A1 (en) * 2003-08-29 2005-03-17 Aton Pharma, Inc. Combination methods of treating cancer
US20050187148A1 (en) * 2004-02-25 2005-08-25 Yoshinori Naoe Antitumor agent
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US8999289B2 (en) * 2005-03-22 2015-04-07 President And Fellows Of Harvard College Treatment of protein degradation disorders
JP2009514889A (ja) * 2005-11-04 2009-04-09 メルク エンド カムパニー インコーポレーテッド 癌を治療するためにｓａｈａ及びボルテゾミブを用いる方法
US20070197568A1 (en) * 2005-11-04 2007-08-23 Paul Bunn Methods of using SAHA and Erlotinib for treating cancer
AU2006311829B8 (en) * 2005-11-04 2013-02-21 Merck Sharp & Dohme Corp. Methods of treating cancers with SAHA, Carboplatin, and Paclitaxel and other combination therapies
AU2007317921A1 (en) * 2006-11-03 2008-05-15 University Of Maryland, Baltimore Methods of using SAHA and Bortezomib for treating multiple myeloma

Similar Documents

Publication Publication Date Title
JP2009514874A5 (enExample)
JP2014526503A5 (enExample)
JP2018520189A5 (enExample)
JP2006504795A5 (enExample)
JP2010518122A5 (enExample)
JP2019516684A5 (enExample)
JP2010521417A5 (enExample)
JP2018531273A5 (enExample)
JP2010065060A (ja) 心不全処置のための複合治療
JP2019218379A5 (enExample)
JP2009517411A5 (enExample)
CN101939001B (zh) 用于治疗卵巢癌的含有紫杉醇的组合
CN104039148A (zh) 组合als疗法
JP2009504774A5 (enExample)
JP2020500868A5 (enExample)
JP2016505050A5 (enExample)
JP2001515041A5 (enExample)
JP2019507786A5 (enExample)
IL272834B2 (en) Amantadine compositions, preparations thereof, and methods of use
JP2013518061A5 (enExample)
JP2019531286A5 (enExample)
EP4045058A1 (fr) Utilisation de nictotinamide mononucléotide (nmn) pour la prevention et/ou le traitement de la polyarthrite rhumatoïde et compositions correspondantes
JP2008533022A5 (enExample)
JP2022177119A5 (enExample)
HRP20251043T1 (hr) Novi oralni farmaceutski pripravak i režim doziranja za terapiju progresivnih fibrozirajućih intersticijskih bolesti pluća